About 400 reports

INTRODUCTION Cancer is known to be one of the leading causes of death worldwide. In 2019, 0.6 million deaths due to cancer are estimated in the US alone. Moreover, the World Health Organization has estimated the number of new cancer cases to rise by 70% over the next 20 years. One of the primary reasons for the high mortality...

  • Cancer
  • Diagnostics
  • Cancer Diagnostics
  • Genetic Testing
  • World
  • United States
  • Cause-Specific Mortality Rate

Trends, opportunities and forecast in liquid biopsy market to 2026 by product (assay kits, instruments, and services), circulating biomarker (circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), cell-free DNA (cfDNA), extracellular vesicles (EVs), and other biomarkers), application (oncology and non-cancer liquid biopsies), clinical...

  • Genetic Testing
  • World
  • Cancer Incidence

Liquid Biopsy Market Global Forecast by Cancer, Product, Sample, Circulating Biomarkers, Regions, Company Analysis A liquid biopsy is an emerging tool for the diagnosis of cancer disease nowadays. The liquid biopsy involves collecting samples and analysing tumours in the blood to diagnose cancer...

  • Genetic Testing
  • World

Global Liquid Biopsy Market 2020-2024 The analyst has been monitoring the liquid biopsy market and it is poised to grow by $ 4.02 bn during 2020-2024, progressing at a CAGR of 38% during the forecast period. Our reports on liquid biopsy market provides a holistic analysis, market size and forecast, trends, growth drivers,...

  • Genetic Testing
  • World
  • Cancer Incidence

Global Lung Cancer Liquid Biopsy Market 2020-2024 The analyst has been monitoring the lung cancer liquid biopsy market and it is poised to grow by $ 292.89 mn during 2020-2024, progressing at a CAGR of 16% during the forecast period. Our reports on the lung cancer liquid biopsy market provide a holistic analysis, market...

  • Lung Cancer
  • Genetic Testing
  • World

## Global Liquid Biopsy - Circulating Tumor DNA (ctDNA) Market & Forecast

  • Genetic Testing
  • World
  • Cancer Incidence
  • Cancer Mortality

Liquid Biopsy Market Report 2020-2030: Forecasts by Product (Instruments, Kits & Reagents, Services), by Sample Type (Blood Samples, Urine Samples, Others), by Biomarker (Circulating Tumour Cell (CTC), Circulating Tumour DNA (ctDNA), Exosomes, Others), by Cancer Type (Breast Cancer, Colorectal Cancer, Liver Cancer, Lung Cancer, Prostate...

  • Genetic Testing
  • Biopsy
  • World
  • APAC
  • Europe
  • Latin America
  • Middle East
  • Africa
  • Disposable Income

The global liquid biopsy market is predicted to reach US$ 9.53 Billion by 2028. Liquid biopsy tests are executed to understand the molecular aspects of cancer across the healthcare and research settings, such as hospitals, physicians, pathological and research laboratories. Liquid biopsy is a non-invasive technology that detects molecular...

  • Genetic Testing
  • World

Liquid Biopsy Market Value forecast, New Business Opportunities and Companies: Outlook By Type, Application, By End User and By Country, 2020- 2026 The study predicts the short term and long term trends that can shape up the future of the Liquid Biopsy market including the COVID-19 pandemic implications for Liquid Biopsys...

  • Biopsy
  • Genetic Testing
  • APAC
  • Central America

Liquid Biopsy Market by Product & Service (Kits & Reagents, Platforms & Instruments, and Services), Circulating Biomarker (Circulating Tumor Cells, Extracellular Vesicles, Circulating Tumor DNA [ctDNA], and Other Biomarkers), Cancer Type (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer, and Other Cancers),...

  • Genetic Testing
  • World

Global Minimally Invasive Biopsy Technologies Market to Reach $4.03 Billion by 2030 Key Questions Answered in the Report: • What are the various minimally invasive biopsy technologies available in the market? • What are the major market drivers, challenges, and opportunities in the global...

  • Biopsy
  • World

## CIRCULATING TUMOR DNA (CTDNA)

  • Genetic Testing
  • World
  • United States
  • North America
  • Europe
  • APAC
  • Cancer Incidence
  • Health Expenditure

Liquid Biopsy Market Size, Outlook and Growth Opportunities, 2019- 2025 Global Liquid Biopsy Market size, Outlook and Opportunities 2019- 2025: By Circulating Biomarker (Extracellular Vesicles (Evs), Circulating Tumor Cells, Circulating Tumor DNA (CTDNA), Cell-Free DNA and  Other Circulating Biomarkers), By Product...

  • Genetic Testing
  • World
  • APAC
  • Asia
  • Europe
  • North America
  • Middle East
  • Africa
  • Latin America
  • Health Expenditure

KEY FINDINGS The global liquid biopsy market is projected to grow with a CAGR of 18.91%, over the forecasted years of 2021 to 2028. The increasing prevalence of cancer in the older populace, the shifting consumer demand for diagnostic centers, the non-invasive nature of liquid biopsy testing, the emergence of tissue/tumor-agnostic...

  • Genetic Testing
  • World
  • APAC
  • Cancer Mortality
  • Cancer Incidence

The global next generation sequencing (NGS) market exhibited double-digit growth during 2015-2020. Next-generation sequencing, or high-throughput sequencing, refers to the process of determining the sequence of nucleotides in a section of the DNA. It includes procedures such as sequencing by synthesis (SBS), ion semiconductor...

  • Molecular Diagnostics
  • World
  • Diabetes Prevalence

ctDNA is the DNA released from a cancerous tumor into the blood stream via biological processes such as apoptosis, necrosis, inefficient phagocytosis, or active secretion.

  • Biopsy
  • APAC
  • North America
  • Breast Screening Coverage
  • Health Expenditure

Latin America Liquid Biopsy Market to Reach $70.9 million by 2025, Reports BIS Research Liquid biopsy is a minimal invasive medical procedure with the ability to detect the presence of molecular cancer biomarkers in the biological fluids.The test principally involves the usage of samples of biological fluids, such as...

  • Genetic Testing
  • Latin America

Next Generation Sequencing Market, Global Forecast, Impact of COVID-19, Industry Trends, Growth, Opportunity By Types of Test, Company Analysis Next-generation sequencing refers to the deep, high-throughput, in-parallel DNA sequencing technologies developed a couple of decades after the Sanger DNA sequencing...

  • Molecular Diagnostics
  • Genome Sequencing
  • World
  • Health Expenditure

InVision ctDNA Assay - NSCLC

  • Lung Cancer
  • Clinical Trial
  • World
  • Europe
  • Medical Devices Sales

## Global Liquid Biopsy - Circulating Tumor DNA (ctDNA) Market & Forecast

  • Genetic Testing
  • World
  • Cancer Incidence
  • Cancer Mortality

‘ESR1 Mutated Metastatic Breast Cancer - Epidemiology Forecast–2030’ report delivers an in-depth understanding of the ESR1 Mutated Metastatic Breast Cancer, historical and forecasted epidemiology as well as the ESR1 Mutated Metastatic Breast Cancer epidemiology trends in the United States, EU5 (Germany, France, Italy, Spain, and the United...

  • Breast Cancer
  • United States
  • Spain
  • France
  • Germany
  • Italy
  • United Kingdom

The kits detect all four mutation classes in solid tumours, complement Roche's NGS ctDNA kits for oncology research.

  • Genomics
  • Europe
  • Drug Approval
  • Diagnostic Revenue

A Multicentre, Open-label, Randomized, Controlled Study of Target Therapy Based on Tumor Molecular Profiling with GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA

  • Clinical Trial
  • World
  • APAC
  • G7

Target Selector ctDNA Test - ALK

  • Clinical Trial
  • United States
  • World
  • North America
  • Hospital Occupancy Rate
  • Medical Devices Sales

Evaluation of ctDNA Guardant LUNAR## Assay In an Average Patient Screening Episode (ECLIPSE) will evaluate whether early signs of colorectal cancer can be detected by a simple blood test.

  • Laboratory
  • World
  • APAC
  • Europe
  • Middle East
  • Health Expenditure
  • Cancer Incidence

Report Scope: The scope of the report includes liquid biopsy technologies, applications, industry subsegments, biomarker technologies, major funding initiatives, patents and companies. The market sizes for liquid biopsy diagnostics are given for 2017, 2018 and 2023 (forecasted). This report reviews liquid biopsy...

  • Genetic Testing
  • World

Detects the presence of ctDNA (circulating tumor Deoxyribonucleic acid) in patient's plasma or serum sample

  • Pancreatic Cancer
  • Clinical Trial
  • United States
  • Smoking Prevalence
  • Drug Approval

into Oncology Testing, ctDNA, laboratory testing, CTC Testing, clinical testing, liquid biopsy, cancer diagnostics, diagnostic

  • Brain Cancer
  • Diagnostics
  • World
  • APAC
  • Middle East
  • Central America
  • Smoking Prevalence
  • Health Expenditure

The company presented association of detectable levels of circulating tumor DNA (ctDNA) w ith disease burden in prostate cancer (PC) at ASCO 2020.

  • Cancer
  • World
  • Drug Approval
  • Medical Technology Density

It is designed to detect the presence of KRAS G##D mutation of circulating tumor DNA (ctDNA) specific to cancer in the patient s blood and urine samples.

  • Clinical Trial
  • United States
  • World
  • North America
  • Illinois
  • India
  • United Kingdom
  • Cause-Specific Mortality Rate
  • Medical Devices Sales